Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 6:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 46 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: aztreonam Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam

NCT03978091
View directory record Official record
Conditions
Bacterial Infection
Interventions
AZACTAM, Ceftazidime-Avibactam
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 18, 2026, 6:41 AM EDT
Completed Phase 3 Interventional Results available

Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa

NCT00757237
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Aztreonam for Inhalation Solution (AZLI), Tobramycin Inhalation Solution (TIS)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
29
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tuscon, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2011 · Synced Oct 18, 2026, 6:41 AM EDT
Completed Phase 3 Interventional Results available

Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis

NCT01313624
View directory record Official record
Conditions
Bronchiectasis
Interventions
AZLI, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
36
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Oct 18, 2026, 6:41 AM EDT
Completed Phase 3 Interventional Results available

International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa

NCT00112359
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZLI 75 mg three times a day (TID), Placebo three times a day (TID)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
40
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2011 · Synced Oct 18, 2026, 6:41 AM EDT
Completed No phase listed Observational

Registry to Monitor the Susceptibility to Aztreonam of Pseudomonas Aeruginosa Isolates From Cystic Fibrosis Patients

NCT01375036
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
31
States / cities
Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 18, 2026, 6:41 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections

NCT00633152
View directory record Official record
Conditions
Bacterial Infection
Interventions
ceftaroline, linezolid, Aztreonam
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
13
States / cities
Buena Park, California • Long Beach, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 18, 2026, 6:41 AM EDT
Completed Phase 3 Interventional Results available

A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.

NCT03329092
View directory record Official record
Conditions
Complicated Intra-abdominal Infection, Hosptial Acquired Pneumonia, Ventilator Associated Pneumonia
Interventions
ATM-AVI, MTZ, MER, COL
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
5
States / cities
Tucson, Arizona • Torrance, California • Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 18, 2026, 6:41 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa

NCT00712166
View directory record Official record
Conditions
Cystic Fibrosis, Lung Infection, Pseudomonas Aeruginosa
Interventions
AZLI 75 mg three times daily (TID), Placebo three times daily (TID)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
34
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2010 · Synced Oct 18, 2026, 6:41 AM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections

NCT00424190
View directory record Official record
Conditions
Bacterial Infections
Interventions
IV Vancomycin plus IV Aztreonam, Ceftaroline
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
15
States / cities
Dothan, Alabama • Long Beach, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 18, 2026, 6:41 AM EDT
Completed No phase listed Observational

Cystic Fibrosis Treatment Adherence Cayston Proof-of-Concept Pilot Study

NCT02179710
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Adherence dashboard motivational interviewing
Behavioral
Lead sponsor
Landon Pediatric Foundation
Other
Eligibility
8 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced Oct 18, 2026, 6:41 AM EDT
Terminated Phase 2 Interventional Results available

Aztreonam Aerosol to Treat Cystic Fibrosis Nasal Disease

NCT02730793
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Oral Aztreonam, Nasal Aztreonam, Nasal Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
7 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 18, 2026, 6:41 AM EDT
Completed Phase 2 Interventional

Study Evaluating Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection

NCT00794586
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
FTI, AZLI, Placebo, AZLI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
36
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2013 · Synced Oct 18, 2026, 6:41 AM EDT
Completed Phase 4 Interventional Results available

Safety Study of Aztreonam Lysine for Inhalation (AZLI) in the Treatment of Early Bronchiolitis Obliterans Syndrome (BOS)

NCT01469364
View directory record Official record
Conditions
Complication of Transplanted Lung
Interventions
Aztreonam Lysine for Inhalation (AZLI), Status Post Lung Transplant
Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Los Angeles, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 18, 2026, 6:41 AM EDT
Recruiting Phase 1 Interventional

Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer

NCT05777603
View directory record Official record
Conditions
Advanced Non Small Cell Lung Cancer
Interventions
aerosolized aztreonam, aerosolized vancomycin, pembrolizumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 18, 2026, 6:41 AM EDT
Completed Phase 3 Interventional Results available

Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections

NCT01811732
View directory record Official record
Conditions
Skin and Subcutaneous Tissue Bacterial Infections
Interventions
Delafloxacin, Vancomycin, Aztreonam, Placebo
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
17
States / cities
Montgomery, Alabama • Anaheim, California • Chula Vista, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Oct 18, 2026, 6:41 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Antibiotic Prophylaxis for Transrectal Prostate Biopsy

NCT01659866
View directory record Official record
Conditions
Infection
Interventions
Ciprofloxacin, trimethoprim-sulfamethoxazole, cefuroxime, ceftriaxone, gentamicin, amikacin, aztreonam, imipenem
Drug
Lead sponsor
Northwestern University
Other
Eligibility
30 Years to 90 Years · Male only
Enrollment
563 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 18, 2026, 6:41 AM EDT
Completed No phase listed Observational

Detection of Reductions in Cystic Fibrosis Airway Inflammation While Using Aztreonam Lysine Solution

NCT01736839
View directory record Official record
Conditions
Cystic Fibrosis in Adults, Chronic Colonization With Pseudomonas Aeruginosa
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Oct 18, 2026, 6:41 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Aztreonam for Pharyngeal Gonorrhea

NCT03867734
View directory record Official record
Conditions
Gonorrhea of Pharynx, Gonorrhea
Interventions
Aztreonam
Drug
Lead sponsor
University of Washington
Other
Eligibility
16 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 18, 2026, 6:41 AM EDT
Completed Phase 3 Interventional Results available

Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways

NCT01404234
View directory record Official record
Conditions
Cystic Fibrosis, Pseudomonas Aeruginosa
Interventions
AZLI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
Up to 12 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
10
States / cities
Aurora, Colorado • Jacksonville, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Oct 18, 2026, 6:41 AM EDT
Terminated Early Phase 1 Interventional

Patients Response to Early Switch To Oral:Osteomyelitis Study

NCT02099240
View directory record Official record
Conditions
Osteomyelitis
Interventions
oral antibiotics, intravenous antibiotics
Drug · Procedure
Lead sponsor
Julio Ramirez
Other
Eligibility
18 Years to 100 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 18, 2026, 6:41 AM EDT
Completed Phase 3 Interventional Results available

Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections

NCT03137173
View directory record Official record
Conditions
Acute Bacterial Skin and Skin Structure Infections
Interventions
ceftobiprole medocaril, vancomycin+aztreonam
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
16
States / cities
Anaheim, California • Chula Vista, California • Fresno, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 18, 2026, 6:41 AM EDT
Completed Phase 2 Interventional

Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection

NCT01055847
View directory record Official record
Conditions
Cystic Fibrosis, CF, Lung Infection, Pseudomonas Aeruginosa
Interventions
Aztreonam for Inhalation (AI), Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
13 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
20
States / cities
Los Angeles, California • Orange, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2010 · Synced Oct 18, 2026, 6:41 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections

NCT01499277
View directory record Official record
Conditions
Complicated Skin and Soft Tissue Infection
Interventions
Ceftaroline fosamil, Vancomycin, Aztreonam
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
10
States / cities
Chula Vista, California • Orlando, Florida • West Palm Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Oct 18, 2026, 6:41 AM EDT
Approved For Marketing No phase listed Expanded access

Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection

NCT00499720
View directory record Official record
Conditions
Cystic Fibrosis, Pseudomonas Aeruginosa Airway Infection
Interventions
Aztreonam Lysine for Inhalation
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
U.S. locations
64
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2011 · Synced Oct 18, 2026, 6:41 AM EDT